In a historic move for psychedelic medicine, Germany has granted the first-ever compassionate use approval for psilocybin in the European Union.
The authorization allows a patient with treatment-resistant depression to receive Filament Health’s botanical psilocybin drug candidate, PEX010, outside of a clinical trial setting.
The treatment will be administered by Dr. Gerhard Gründer at the Central Institute of Mental Health’s Department of Molecular Neuroimaging. Dr. Gründer emphasized the significance of the decision, noting that treatment-resistant depression affects up to 30% of people diagnosed with major depressive disorder and remains one of psychiatry’s most difficult conditions to manage.
“This is a landmark moment for the field of psychedelic medicine in the European Union,” said Dr. Gründer. “Psilocybin has demonstrated significant promise as a novel therapeutic option, and this approval marks an important step toward expanding access for those in urgent need.”
The German approval reinforces Filament Health’s position as a leader in the development of natural psychedelic drug candidates. PEX010, the company’s standardized botanical psilocybin formulation, will be the first psilocybin product legally administered to a patient in the EU under a compassionate use program.
“We’re incredibly proud that our drug product will be the first psilocybin to be administered under compassionate use in the EU,” said Filament CEO Benjamin Lightburn. “It’s a validation of Filament’s ongoing efforts to make safe, standardized psychedelic medicines available to those who need them most.”
Based in Vancouver, Filament Health is a clinical-stage psychedelic drug development company focused on producing natural, GMP-quality drug candidates for use in regulated markets.
More articles from The Marijuana Herald:
